Literature DB >> 26698952

Pneumonic Plague: The Darker Side of Yersinia pestis.

Roger D Pechous1, Vijay Sivaraman2, Nikolas M Stasulli1, William E Goldman3.   

Abstract

Inhalation of the bacterium Yersinia pestis results in primary pneumonic plague. Pneumonic plague is the most severe manifestation of plague, with mortality rates approaching 100% in the absence of treatment. Its rapid disease progression, lethality, and ability to be transmitted via aerosol have compounded fears of the intentional release of Y. pestis as a biological weapon. Importantly, recent epidemics of plague have highlighted a significant role for pneumonic plague during outbreaks of Y. pestis infections. In this review we describe the characteristics of pneumonic plague, focusing on its disease progression and pathogenesis. The rapid time-course, severity, and difficulty of treating pneumonic plague highlight how differences in the route of disease transmission can enhance the lethality of an already deadly pathogen.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Yersinia pestis; plague; pneumonic plague

Mesh:

Substances:

Year:  2015        PMID: 26698952     DOI: 10.1016/j.tim.2015.11.008

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  45 in total

1.  Yersinia pestis Pla Protein Thwarts T Cell Defense against Plague.

Authors:  Stephen T Smiley; Frank M Szaba; Lawrence W Kummer; Debra K Duso; Jr-Shiuan Lin
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

2.  Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.

Authors:  Danielle A Wagner; Sean M Kelly; Andrew C Petersen; Nathan Peroutka-Bigus; Ross J Darling; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2019-10-11       Impact factor: 8.947

Review 3.  Neuroterrorism Preparedness for the Neurohospitalist.

Authors:  Maj Samuel A Ralston; Maj Brian P Murray; Daniel Vela-Duarte; Karen D Orjuela; Daniel M Pastula
Journal:  Neurohospitalist       Date:  2018-10-21

Review 4.  Yersinia pestis: the Natural History of Plague.

Authors:  R Barbieri; M Signoli; D Chevé; C Costedoat; S Tzortzis; G Aboudharam; D Raoult; M Drancourt
Journal:  Clin Microbiol Rev       Date:  2020-12-09       Impact factor: 26.132

5.  Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.

Authors:  William Bowen; Lalit Batra; Amanda R Pulsifer; Esma S Yolcu; Matthew B Lawrenz; Haval Shirwan
Journal:  Vaccine       Date:  2019-08-12       Impact factor: 3.641

6.  A Dual Role for the Plasminogen Activator Protease During the Preinflammatory Phase of Primary Pneumonic Plague.

Authors:  Srijon K Banerjee; Samantha D Crane; Roger D Pechous
Journal:  J Infect Dis       Date:  2020-07-06       Impact factor: 5.226

7.  Modification of the Pulmonary MyD88 Inflammatory Response Underlies the Role of the Yersinia pestis Pigmentation Locus in Primary Pneumonic Plague.

Authors:  Rachel M Olson; Miqdad O Dhariwala; William J Mitchell; Jerod A Skyberg; Deborah M Anderson
Journal:  Infect Immun       Date:  2021-02-16       Impact factor: 3.441

8.  Depletion of Glucose Activates Catabolite Repression during Pneumonic Plague.

Authors:  Jeremy T Ritzert; Wyndham W Lathem
Journal:  J Bacteriol       Date:  2018-05-09       Impact factor: 3.490

9.  Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics.

Authors:  Jourdan A Andersson; Jian Sha; Michelle L Kirtley; Emily Reyes; Eric C Fitts; Sara M Dann; Ashok K Chopra
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

10.  Mutational Effects on Carbapenem Hydrolysis of YEM-1, a New Subclass B2 Metallo-β-Lactamase from Yersinia mollaretii.

Authors:  Paola Sandra Mercuri; Roberto Esposito; Sylvie Blétard; Stefano Di Costanzo; Mariagrazia Perilli; Frédéric Kerff; Moreno Galleni
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.